Posts by Clarion
Key Lessons for Future Cell & Gene Therapies
By Heather Drexler, Anna May Fitch, Caleb Rhodes, Carolyn Zheng, Olivia Okoli, Seth Henks, Ellen Edenberg, and Bobby Moy The first cell and gene therapy products have launched, but the development pipeline suggests a potential explosion in the space moving forward with hundreds of assets in clinical and preclinical development across a variety of platforms…
Read MoreKeytruda approval for TMB-high tumors: A double-edged sword?
By Martin Strebl-Bantillo and Dennis Chang Immune checkpoint inhibitors (ICIs)—including anti-CTLA4, anti-PD1, and anti-PD-L1 antibodies—have transformed the landscape of cancer treatment, reshaped standards of care, and for some patients cured their disease. To date, the FDA has approved 7 ICI agents1 that together drove more than 24 billion USD in global sales in 20192. At…
Read More